Chongqing Lummy Pharmaceutical Co Ltd (300006):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Chongqing Lummy Pharmaceutical Co Ltd (300006) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8195
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Chongqing Lummy Pharmaceutical Co Ltd (Lummy) is a pharmaceutical company that provides pharmaceutical ingredients and drugs and related products. The company’s products include antibacterial drugs, antifungal drugs, tumor drugs, immune system agents, blood system agents, cardiovascular system agents, antiviral agents, and digestive system agents, among others. It also provides nervous system agents, electrolyte and acid-base, base large infusions, liver disease auxiliaries, and active pharmaceutical ingredients, among others. Lummy’s active pharmaceutical ingredients comprise atosiban acetates, thymalfasin, terlipressin acetate, desmopressin acetate, carbetocin and carbon nano-particles, among others. The company operates through its distribution network in China and Taiwan. Lummy is headquartered in Chongqing, China.

Chongqing Lummy Pharmaceutical Co Ltd (300006) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Argos Therapeutics Enters into Licensing Agreement with Lummy HK 10
Equity Offering 11
Chongqing Lummy Pharma to Raise USD141 Million in Private Placement of Shares 11
Debt Offering 12
Chongqing Lummy Pharma Plans to Raise up to USD77 Million in Private Placement of Bonds 12
Acquisition 13
Chongqing Lummy Pharma Plans to Acquire 35% Stake in Tibetan Teda Health and Medicine 13
Chongqing Lummy Pharma Acquires 30% Stake In Pharma Company For USD16 Million 14
Chongqing Lummy Pharma Completes Acquisition Of Remaining 40% Stake In Sichuan Hygien Pharma From Chongqing Venture Capital For US$7 Million 15
Chongqing Lummy Pharma To Acquire 60% Stake In Chengdu Jinxing Sanum-Kehlbeck For US$32 Million 16
Chongqing Lummy Pharmaceutical Co Ltd – Key Competitors 17
Chongqing Lummy Pharmaceutical Co Ltd – Key Employees 18
Chongqing Lummy Pharmaceutical Co Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chongqing Lummy Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Argos Therapeutics Enters into Licensing Agreement with Lummy HK 10
Chongqing Lummy Pharma to Raise USD141 Million in Private Placement of Shares 11
Chongqing Lummy Pharma Plans to Raise up to USD77 Million in Private Placement of Bonds 12
Chongqing Lummy Pharma Plans to Acquire 35% Stake in Tibetan Teda Health and Medicine 13
Chongqing Lummy Pharma Acquires 30% Stake In Pharma Company For USD16 Million 14
Chongqing Lummy Pharma Completes Acquisition Of Remaining 40% Stake In Sichuan Hygien Pharma From Chongqing Venture Capital For US$7 Million 15
Chongqing Lummy Pharma To Acquire 60% Stake In Chengdu Jinxing Sanum-Kehlbeck For US$32 Million 16
Chongqing Lummy Pharmaceutical Co Ltd, Key Competitors 17
Chongqing Lummy Pharmaceutical Co Ltd, Key Employees 18
Chongqing Lummy Pharmaceutical Co Ltd, Subsidiaries 19

List of Figures
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Chongqing Lummy Pharmaceutical Co Ltd (300006):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • H&R Block, Inc.:戦略・SWOT・企業財務分析
    H&R Block, Inc. - Strategy, SWOT and Corporate Finance Report Summary H&R Block, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • SSP Group Limited (Foodservice):企業の戦略・SWOT・財務情報
    SSP Group Limited (Foodservice) - Strategy, SWOT and Corporate Finance Report Summary SSP Group Limited (Foodservice) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Australian Pharmaceutical Industries Ltd (API):企業の財務・戦略的SWOT分析
    Australian Pharmaceutical Industries Ltd (API) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Vedanta Resources Ltd:企業の戦略的SWOT分析
    Vedanta Resources Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Equinix Inc (EQIX):企業の財務・戦略的SWOT分析
    Equinix Inc (EQIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • RISE Life Science Corp:企業のM&A・事業提携・投資動向
    RISE Life Science Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's RISE Life Science Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Biotest AG (BIO)-製薬・医療分野:企業M&A・提携分析
    Summary Biotest AG (Biotest) is a provider of pharmaceutical and biotherapeutic drugs which develops, manufactures and distributes biological medicines through its value chain from preclinical and clinical development to sales. Its main products comprise clotting factors, immunoglobulins, albumin an …
  • Catholic Health Initiatives:企業のM&A・事業提携・投資動向
    Catholic Health Initiatives - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Catholic Health Initiatives Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Nordion (Canada) Inc:企業の戦略的SWOT分析
    Nordion (Canada) Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Superdry Plc:企業の戦略・SWOT・財務分析
    Superdry Plc - Strategy, SWOT and Corporate Finance Report Summary Superdry Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Lakeland Financial Corporation:企業の戦略・SWOT・財務情報
    Lakeland Financial Corporation - Strategy, SWOT and Corporate Finance Report Summary Lakeland Financial Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Qatar Electricity & Water Co QPSC (QEWS):企業の財務・戦略的SWOT分析
    Qatar Electricity & Water Co QPSC (QEWS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Piramal Glass Pvt Ltd:企業の戦略・SWOT・財務情報
    Piramal Glass Pvt Ltd - Strategy, SWOT and Corporate Finance Report Summary Piramal Glass Pvt Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Brain Resource Ltd (BRC):企業の財務・戦略的SWOT分析
    Summary Brain Resource Ltd (BRL) is a healthcare service provider that offers therapies. The company carries out research and development of brain products. Its products comprise iSPOT, Total Brain and MyBrainSolutions. BRL’s MyBrainSolutions is a brain health solution to know and train brain for pe …
  • Tobu Railway Co Ltd:企業の戦略・SWOT・財務分析
    Tobu Railway Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Tobu Railway Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • SSAB AB:企業の戦略・SWOT・財務情報
    SSAB AB - Strategy, SWOT and Corporate Finance Report Summary SSAB AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Duke Energy Corp:企業の発電所・SWOT分析2018
    Duke Energy Corp - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (e …
  • Fenner PLC (FENR):企業の財務・戦略的SWOT分析
    Summary Fenner PLC (Fenner) a subsidiary of Michelin SCA, is a provider of reinforced polymer technology. The company operates in the areas of advanced engineered products and engineered conveyor solutions. Its product portfolio includes heavyweight conveyor belt, high performance polymer components …
  • Ultra Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Ultra Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Ultra Petroleum Corp (Ultra) is an independent upstream company, which develops, produces, operates, explores, and acquires oil and natural gas properties. It develops long-life natural gas rese …
  • Boiron SA:企業の戦略・SWOT・財務分析
    Boiron SA - Strategy, SWOT and Corporate Finance Report Summary Boiron SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆